Global CGM Market to Surpass $14.1 Billion by 2033, Driven by Diabetes Surge and Tech Advancements

Continuous Glucose Monitoring Market Overview
According to Renub Research, the global market for continuous glucose monitoring (CGM) is projected to grow significantly. It is projected to be worth around US$6.82 billion in 2024 and US$14.1 billion in 2033. Driven by a robust compound annual growth rate (CAGR) of 8.41% from 2024 to 2033.
Continuous glucose monitoring (CGM) devices offer a simple and efficient method for managing diabetes and are less intrusive. Additionally, they can identify sharp variations in blood glucose levels, which helps to avoid hypoglycemia. With the aid of a sensor, the CGM devices make it easier to analyze blood glucose levels at various intervals. Through a wireless network, patients can enter their respective readings into the diabetes management program, allowing them to understand better and control their condition. Common risk factors for complications from diabetes include high blood pressure, high cholesterol, obesity, smoking, and physical inactivity.
One of the factors fueling the market expansion for continuous glucose monitoring (CGM) devices is the rise in the prevalence of diabetes brought on by age, obesity, and bad lifestyle choices. One of the leading causes of diabetes is obesity. In 2022, there were more than 1 billion obese people globally, including 650 million adults, 340 million adolescents, and 39 million children, according to the WHO. This figure keeps rising. According to WHO, if current trends continue, over 167 million adults and children will suffer from deteriorating health conditions as a result of their weight problems by 2025. Apart from fat, diabetes is also on the rise throughout the world.
According to predictions from the International Diabetes Federation (IDF), 537 million individuals (aged 20-79) had diabetes in 2021; by 2040, that figure is predicted to rise to 642 million. According to the IDF, diabetes is becoming more common worldwide, with low- and middle-income nations seeing the most significant increases.

Key information covered in the report.
Base Year - 2024
Historical Period - 2020-2024
Market Forecast - 2025-2033
Market - US$ Billion

Request a free sample copy of the report: https://www.renub.com/global-cgm-market-users-reimbursement-policy-continuous-glucose-monitoring-p.php

Trends in the Continuous Glucose Monitoring Industry
Growing Diabetes Prevalence Drives Market Growth for Continuous Glucose Monitoring
One of the primary factors driving the growth of the continuous glucose monitoring (CGM) market is the increasing prevalence of diabetes worldwide. The International Diabetes Federation predicts that between 2021 and 2045, the number of people with diabetes will rise by an astounding 134% in Africa and 24% in North America and the Caribbean. This worldwide trend underscores the growing demand for advanced glucose monitoring systems, establishing continuous glucose monitoring (CGM) devices as essential tools for effective diabetes care. The increasing prevalence of diabetes in various geographic areas is driving innovation in glucose monitoring technology, creating a sizable market for continuous glucose monitoring (CGM) producers.
Men in the United States had greater rates of both total and diagnosed diabetes than women between August 2021 and August 2023, according to data released by the National Center for Health Statistics in November 2024. 15.8% of individuals had diabetes overall, of whom 11.3% had a diagnosis, and 4.5% did not. The prevalence of diabetes was 18.0% overall and 12.9% in males, compared to 13.7% and 9.7% in women, respectively. Furthermore, the prevalence of diabetes rose with weight. In those who were underweight or of normal weight, it was 6.8%; in those who were overweight, it was 12.3%; and in those who were obese, it was 24.2%. Similar trends were seen in diagnosed diabetes, which increased from 5.2% in underweight or normal-weight adults to 9.5% in overweight people and 16.3% in obese people.

End User
• Hospitals
• Homecare Settings
• Others

What technological advancements are driving growth in CGM devices
• Reduced Size and Increased Sensor Life
Longer-lasting, smaller sensors increase compliance and lessen user discomfort. For instance, Dexcom's G7 (15-day wear) and Abbott's FreeStyle Libre 14-day sensors reduce the need for frequent replacements without sacrificing accuracy.
Long-term monitoring is possible with implanted devices, such as Senseonics' Eversense E3 (with a 6-month lifetime), which requires no regular maintenance.
• Predictive analytics and artificial intelligence
Proactive management is enabled by machine learning algorithms that can predict glucose variations up to 60 minutes in advance. Personalized insights and automatic suggestions are offered by Roche's Accu-Chek SmartGuide system, which is driven by AI, and Medtronic's Guardian Connect.
AI integration enhances glycemic control, reduces manual interventions, and enhances data interpretation.
• Multi-sensor and non-invasive technologies
The goal of new non-invasive CGMs, such as the K'Watch and GlucoRx's multi-sensor system, is to eliminate fingerstick calibrations; however, most are still in the testing stage.
The accuracy and dependability of enzyme-based electrochemical sensors are enhanced, especially in minimally invasive devices.
• Smooth Integration of Devices
Real-time glucose monitoring and automatic insulin adjustments are made possible by the communication between smartphones and insulin pumps. Abbott's FreeStyle Libre connects to mobile applications for real-time input, while Dexcom G7 integrates with pumps.
Cloud-based technologies enhance clinical decision-making by enabling healthcare practitioners to monitor patients remotely.
• OTC (Over-the-Counter) Growth
By allowing non-diabetics to track their metabolic health, the FDA's approval of over-the-counter CGMs (such as Dexcom Stelo) expands the market beyond typical consumers.

Countries
North America
• United States
• Canada
Europe
• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand
Latin America
• Brazil
• Mexico
• Argentina
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Important Businesses & Market Share Information
Market participants like Dexcom, Inc., Abbott, Medtronic, Ypsomed AG, Senseonics Holdings, Inc., A. Menarini Diagnostics S.r.l. and Signos, Inc. dominate the consolidated market. To increase their market share, the majority of these top businesses engage in strategic alliances, mergers, acquisitions, and geographical expansions. By pooling the knowledge and efforts of many companies, market participants are forming partnerships and working together to expand, develop, and become more competitive. Abbott, Ypsomed AG, and A. Menarini Diagnostics S.r.l. are significant firms participating.
In January 2024, for example, Abbott and Tandem Diabetes Care, Inc. announced that their Control-IQ-enabled t: slim X2 insulin pump was the first Automated Insulin Delivery (AID) system to integrate with Abbott's newest Continuous Glucose Monitoring (CGM) technology, the FreeStyle Libre 2 Plus sensor.

What cutting-edge substances or sensors may newcomers create for non-invasive glucose testing?
For new competitors entering the non-invasive glucose monitoring business, several cutting-edge materials and sensor technologies provide encouraging prospects:
• Innovative Nanocomposite and Flexible Substances
Graphene Quantum Dots/Polyaniline (N-GQDs/PANI) Nanocomposites doped with nitrogen:
When combined with glucose oxidase, these flexible nanocomposite layers exhibit excellent sensitivity, selectivity, and stability for detecting glucose in sweat, continuing to function even when bent continuously. They are, therefore, perfect for skin-adapted, wearable sensors.
Nanosheets of nickel oxide (NiO) atop graphene oxide films:
Non-enzymatic electrochemical glucose detection with a quick response, low detection limit, and broad detection range is made possible by NiO-based sensors built on graphene oxide templates, providing new approaches for high-performance, reasonably priced sensors.
• Subcutaneous and Skin-Like Electrochemical Sensors
Twin Channel Electrochemical (ETC) Sensors:
High sensitivity and real-time correlation with blood glucose levels are provided by ultra-thin, skin-like biosensors featuring twin electrochemical channels that can directly collect and detect glucose from blood vessels beneath the skin.
Component
• Sensors
• Transmitters
• Receivers

Recent Developments in Continuous Glucose Monitoring Market
• Medtronic plc announced in January 2024 that the CE Mark has been approved for its MiniMed 780G system with Simplera Sync. A two-step insertion procedure is simplified with Simplera Sync, a technique that enhances the user experience. Furthermore, the size of this new sensor is half that of its predecessors. A restricted release of the MiniMed 780G system with Simplera Sync sensor is planned for spring 2024 in Europe, with a gradual commercial introduction to follow in the summer of the same year.
• Tandem Diabetes Care's integration of the Dexcom G7 Continuous Glucose Monitor (CGM) with the slim X2 insulin pump was announced by Dexcom, Inc. in December 2023.

Key Players Analysis
• Abbott Laboratories
• Roche
• Tandem Diabetes Care
• DexCom Inc.
• Senseonics Holdings Inc.
• Ypsomed Holding AG
• Medtronic Plc.
• I-Sens Inc.

New Reports publish
https://www.renub.com/dental-insurance-market-p.php
https://www.renub.com/united-states-assisted-reproductive-technology-market-p.php
https://www.renub.com/home-healthcare-market-p.php

Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: mailto:rajat@renub.com

About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

This release was published on openPR.